4-nitrophenyl thiazol-4-ylmethyl carbonate | 144163-95-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-nitrophenyl thiazol-4-ylmethyl carbonate
• 英文别名: thiazol-4-ylmethyl (4-nitrophenyl)carbonate；thiazole-4-ylmethyl (4-nitrophenyl)carbonate；Thiazol-4-ylmethyl 4-nitrophenyl carbonate；(4-nitrophenyl) 1,3-thiazol-4-ylmethyl carbonate
• CAS: 144163-95-1
• 化学式: C₁₁H₈N₂O₅S
• 分子量: 280.261
• InChiKey: CMKSGOMYRWZDEQ-UHFFFAOYSA-N

物化性质

• 沸点：
  475.3±45.0 °C(Predicted)
• 密度：
  1.485±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  123
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-nitrophenyl thiazol-4-ylmethyl carbonate 在 4-二甲氨基吡啶 氢溴酸 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 thiazol-4-ylmethyl(7-azaspiro[3.5]non-2-yl)carbamate
  参考文献：
  名称：

  DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

  摘要：

  该发明涉及一般式（I）的化合物，其中R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基、NR8R9基团中的一种；m、n、o和p分别是等于0、1、2或3的整数；A是共价键或C1-8-烷基烯基团；R1是可选择取代的芳基或杂环芳基团；R3是氢原子或氟原子或C1-6-烷基或三氟甲基基团；R4是可选择取代的5-成员杂环化合物；所述化合物为盐基或酸加合盐形式。该发明还涉及其治疗用途。

  公开号：

  US20110319381A1

文献信息

• CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20120095040A1

  公开（公告）日：2012-04-19

  The invention relates to compounds of the general formula (I) where: R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy, or NR 8 R 9 group; m, n, o and p independently are a number from 0 to 3; A is a covalent bond, an oxygen atom, a C 1-6 -alkylene group or a —O—C 1-6 -alkylene group in which the end that is an oxygen atom is bonded to the R 1 group while the end that is an alkylene group is bonded to the carbon of the bicyclic compound; R 1 is an optionally substituted aryl or heteroaryl group; R 3 is a hydrogen or fluorine atom or a C 1-6 -alkyl or trifluoromethyl group; R 4 is an optionally substituted 5-membered heterocyclic compound; wherein the compounds can be in the state of a base or an acid addition salt. The invention can be used in therapeutics.

  该发明涉及一般式（I）的化合物，其中：R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；m、n、o和p独立地是从0到3的数字；A是共价键、氧原子、C1-6-烷基烯基团或—O—C1-6-烷基烯基团，其中一个端是氧原子与R1基团结合，而另一个端是烷基烯基团与双环化合物的碳结合；R1是可选择取代的芳基或杂环芳基；R3是氢原子或氟原子或C1-6-烷基或三氟甲基基团；R4是可选择取代的5-成员杂环化合物；其中这些化合物可以处于碱性或酸性盐的状态。该发明可用于治疗学。
• 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20120129830A1

  公开（公告）日：2012-05-24

  The invention relates to compounds of the general formula (I) where: R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy, or NR 8 R 9 group; m, n, o and p independently are a number from 0 to 3, provided that m+n≦7 and that o+p≦7; A is a covalent bond, an oxygen atom, a C 1-6 -alkylene group or a —O—C 1-6 -alkylene group in which the end that is an oxygen atom is bonded to the R 1 group and the end that is an alkylene group is bonded to the carbon of the bicyclic compound; R 1 is an optionally substituted aryl or heteroaryl group; R 3 is a hydrogen or fluorine atom or a C 1-6 -alkyl or trifluoromethyl group; R 4 is an optionally substituted 5-membered heterocyclic compounds; wherein the compounds can be in the state of a base or an acid addition salt. The invention can be used in therapeutics.

  该发明涉及一般式（I）的化合物，其中：R2为氢或氟原子，或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；m、n、o和p独立地为0到3之间的数字，但要求m+n≦7且o+p≦7；A为共价键、氧原子、C1-6-烷基烯基团或—O—C1-6-烷基烯基团，其中以氧原子为端点的部分与R1基团结合，以烷基烯基团为端点的部分与双环化合物的碳结合；R1为可选择取代的芳基或杂环芳基；R3为氢或氟原子，或C1-6-烷基或三氟甲基基团；R4为可选择取代的5-成员杂环化合物；其中这些化合物可以处于碱性或酸性盐的状态。该发明可用于治疗学。
• ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20110212963A1

  公开（公告）日：2011-09-01

  The invention relates to the novel products of formula (I): in which: Ra represents H, Hal, aryl or heteroaryl, which is optionally substituted; Rb represents H, Rc, —COORc-CO—Rc or —CO—NRcRd; where Rc represents alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, all optionally substituted; Rd represents H, alk or cycloalkyl; these products being in all the isomer forms and the salts, as medicaments, in particular as MET inhibitors.

  这项发明涉及公式(I)的新产品：其中：Ra代表H、Hal、芳基或杂环芳基，可选地取代；Rb代表H、Rc、—COORc-CO—Rc或—CO—NRcRd；其中Rc代表烷基、环烷基、杂环烷基、芳基和杂环芳基，均可选地取代；Rd代表H、烷基或环烷基；这些产品以所有异构体形式和盐的形式作为药物，特别作为MET抑制剂。
• 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20120136026A1

  公开（公告）日：2012-05-31

  The invention relates to compounds of the general formula (I) where: R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy, or NR 8 R 9 group; m and p have a value of 1; n and o have the same value which is 0 or 1; A is a covalent bond or a C 1-8 -alkylene group; R 1 is an optionally substituted aryl or heteroaryl group; R 3 is a hydrogen or fluorine atom or a C 1-6 -alkyl group or a trifluoromethyl group; R 4 is an optionally substituted 5-membered heterocyclic compound; wherein the compounds can be in the state of a base or an acid addition salt. The present invention can be used in therapeutics.

  该发明涉及一般式（I）的化合物，其中：R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；m和p的值为1；n和o具有相同的值，为0或1；A是共价键或C1-8-烷基烯基团；R1是可选择取代的芳基或杂环芳基团；R3是氢原子或氟原子或C1-6-烷基或三氟甲基基团；R4是可选择取代的5-成员杂环化合物；其中这些化合物可以处于碱态或酸盐加合物的状态。本发明可用于治疗学。
• [EN] ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION<br/>[FR] DÉRIVÉS CARBAMATES ALKYL-HÉTÉROCYCLIQUES, LEUR PRÉPARATION ET LEUR APPLICATION THÉRAPEUTIQUE
  申请人：SANOFI AVENTIS

  公开号：WO2011089550A1

  公开（公告）日：2011-07-28

  The invention relates to compounds corresponding to the general formula (I) : in which R2 represents a hydrogen, fluorine, hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy or -NR8R9; n and m represent, independently of one another, an integer equal to 1, 2 or 3, it being understood that the sum m+n is at most equal to 5; A represents a covalent bond, an oxygen, a C1-6-alkylene or -O-C1-6-alkylene; R1 represents a phenyl or a heterocycle which is optionally substituted; R3 represents a hydrogen, fluorine, C1-6-alkyl or trifluoromethyl; R4 represents an optionally substituted 5-membered heterocycle; in the form of the base or of an addition salt with an acid; with the exclusion of 5-methylisoxazol-3-ylmethyl 4-hydroxy-4- (4- chlorophenyl) piperidine-1-carboxylate. The invention also relates to a process for the preparation of the compounds of formula (I), to compositions comprising them and to their therapeutic application.

  本发明涉及与通式（I）相对应的化合物： 其中，R2表示氢、氟、羟基、氰基、三氟甲基、C1-6烷基、C1-6烷氧基或-NR8R9；n和m分别表示等于1、2或3的整数，其中m+n的总和最多等于5；A表示共价键、氧、C1-6-烷基亚甲基或-O-C1-6-烷基亚甲基；R1表示苯基或可选取代的杂环；R3表示氢、氟、C1-6烷基或三氟甲基；R4表示可选取代的5-成员杂环；以碱或酸的加成盐的形式存在。 本发明还涉及制备通式（I）化合物的方法、包含它们的组合物以及它们的治疗应用，但不包括5-甲基异噁唑-3-基甲基4-羟基-4-（4-氯苯基）哌啶-1-羧酸酯。